Evidence map›Paper›PMID 31747312›Full record

ArticleAmerican journal of physiology. Cell physiology2020

Real-time visualization of titin dynamics reveals extensive reversible photobleaching in human induced pluripotent stem cell-derived cardiomyocytes.

Adrian G Cadar, Tromondae K Feaster, Kevin R Bersell, Lili Wang, TingTing Hong, Joseph A Balsamo, Zhentao Zhang, Young Wook Chun, Young-Jae Nam, Michael Gotthardt and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of physiology. Cell physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Adrian G CadarDepartment of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee.ORCID 0000-0002-1221-0764
Tromondae K FeasterDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Kevin R BersellDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Lili WangDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee.
TingTing HongSmidt Heart Institute and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Joseph A BalsamoDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Zhentao ZhangDepartment of Medicine, Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, Tennessee.
Young Wook ChunDepartment of Medicine, Division of Cardiovascular Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Young-Jae NamDepartment of Medicine, Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, Tennessee.
Michael GotthardtNeuromuscular and Cardiovascular Cell Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Björn C KnollmannDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Dan M RodenDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Chee C LimDepartment of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee.
Charles C HongDepartment of Medicine, Division of Cardiovascular Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Vanderbilt University · USUniversity of Maryland, Baltimore · USCedars-Sinai Medical Center · USMax Delbrück Center · DE

Funding

The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Understanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2015 to 2019
$13.0M
CLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM007569 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Bjorn C Knollmann · 1985 to 2026
$12.4M
Vanderbilt/Meharry Initiative for Minority Student DvptR25GM062459 · NIGMS · VANDERBILT UNIVERSITY · PI VELEZ EDWARDS, DIGNA R · 2002 to 2020
$10.4M
Toward a Mechanism-Based Approach to Treating Cardiac ArrhythmiaR35HL144980 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KNOLLMANN, BJORN C · 2019 to 2025
$7.1M
Regulation of Ion Channels at BIN1-induced T-tubule MicrodomainsR01HL133286 · NHLBI · UNIVERSITY OF UTAH · PI HONG, TINGTING · 2016 to 2020
$2.2M
Regulation and Maintenance of Cardiac Muscle Sarcomere IntegrityR01HL095813 · NHLBI · VANDERBILT UNIVERSITY · PI HONG, CHARLES C · 2010 to 2014
$2.1M
Novel Approach to Enhance Myocardial Performance and Improve Heart Failure OutcomeR01HL135129 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HONG, CHARLES C · 2018 to 2021
$1.6M
NCATS NIH HHS UL1 TR000445NHLBI NIH HHS R01 HL095813NHLBI NIH HHS R01 HL133286NHLBI NIH HHS R01 HL135129NHLBI NIH HHS R35 HL144980NIGMS NIH HHS P50 GM115305NIGMS NIH HHS R25 GM062459NIGMS NIH HHS T32 GM007569
6 · The paper itself

Abstract

Fluorescence recovery after photobleaching (FRAP) has been useful in delineating cardiac myofilament biology, and innovations in fluorophore chemistry have expanded the array of microscopic assays used. However, one assumption in FRAP is the irreversible photobleaching of fluorescent proteins after laser excitation. Here we demonstrate reversible photobleaching regarding the photoconvertible fluorescent protein mEos3.2. We used CRISPR/Cas9 genome editing in human induced pluripotent stem cells (hiPSCs) to knock-in mEos3.2 into the COOH terminus of titin to visualize sarcomeric titin incorporation and turnover. Upon cardiac induction, the titin-mEos3.2 fusion protein is expressed and integrated in the sarcomeres of hiPSC-derived cardiomyocytes (CMs). STORM imaging shows M-band clustered regions of bound titin-mEos3.2 with few soluble titin-mEos3.2 molecules. FRAP revealed a baseline titin-mEos3.2 fluorescence recovery of 68% and half-life of ~1.2 h, suggesting a rapid exchange of sarcomeric titin with soluble titin. However, paraformaldehyde-fixed and permeabilized titin-mEos3.2 hiPSC-CMs surprisingly revealed a 55% fluorescence recovery. Whole cell FRAP analysis in paraformaldehyde-fixed, cycloheximide-treated, and untreated titin-mEos3.2 hiPSC-CMs displayed no significant differences in fluorescence recovery. FRAP in fixed HEK 293T expressing cytosolic mEos3.2 demonstrates a 58% fluorescence recovery. These data suggest that titin-mEos3.2 is subject to reversible photobleaching following FRAP. Using a mouse titin-eGFP model, we demonstrate that no reversible photobleaching occurs. Our results reveal that reversible photobleaching accounts for the majority of titin recovery in the titin-mEos3.2 hiPSC-CM model and should warrant as a caution in the extrapolation of reliable FRAP data from specific fluorescent proteins in long-term cell imaging.

Indexed as

Cell DifferentiationFluorescence Recovery After PhotobleachingMicroscopy, FluorescenceMicroscopy, VideoAdultCell LineConnectinHumansInduced Pluripotent Stem CellsKineticsLuminescent ProteinsMaleMyocytes, CardiacRecombinant Fusion ProteinsReproducibility of ResultsSarcomeresConnectinLuminescent ProteinsRecombinant Fusion ProteinsTTN protein, humanFRAPhiPSC-CMmEos3.2sarcomeretitin

Identifiers

PMID31747312
PMCPMC6985833
OpenAlexW2990240006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.